Multicenter Canadian case series of pediatric patients less than 12years of age with moderate‐to‐severe atopic dermatitis treated with dupilumab

BackgroundDupilumab is approved for moderate‐severe atopic dermatitis (AD) in patients aged ≥6 months by the US Food and Drug Administration and Health Canada; however, there are little real‐world data because providers have limited practical experience with this recently approved therapy.Objectives...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Pediatric dermatology 2024-01, Vol.41 (1), p.5-11
Hauptverfasser:	Sylvia Martinez‐Cabriales, Marcoux, Danielle, Carmen Liy‐Wong, Prajapati, Vimal H, Sibbald, Cathryn, Cunningham, Natalie, Lansang, Perla, Tonkin, Rochelle, Joseph, Marissa, Wong, Lauren, Spring, Shanna, Gavigan, Genevieve, Ramien, Michele
Format:	Artikel
Sprache:	eng
Schlagworte:	Age Atopic dermatitis Dermatitis Dermatology Eczema FDA approval Monoclonal antibodies Patients Pediatrics Pruritus Quality of life
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!